---
title: CRO Daily News — November 6, 2026
slug: daily-news-2026-11-06-cro
site: cro
post_kind: news
byline: BioBM
description: November 6 CRO daily: Insights on FDA Inspections of APAC Clinical Trial Sites and Their Quality Improvements — Smaller biotechs must adapt their strategies…
canonical_url: https://www.cro.directory/posts/daily-news-2026-11-06-cro
published_at: 2026-11-06T23:59:46.748Z
last_updated: 2026-11-07T00:01:26.760Z
---

### Insights on FDA Inspections of APAC Clinical Trial Sites and Their Quality Improvements
- FDA inspection findings indicate that quality issues at APAC clinical trial sites are comparable to those in the US and Europe.
- China has significantly reduced approval timelines for clinical trials, now averaging six and a half months, with some reviews taking as little as 30 days.

**Operational Impact**

Smaller biotechs must adapt their strategies for APAC Phase III trials, focusing on site selection and partnering with experienced CROs to leverage faster recruitment and lower costs.

*Source: [Applied Clinical Trials RSS](https://www.appliedclinicaltrialsonline.com/view/fda-inspections-reveal-quality-apac-clinical-trial-sites)*

## References

1. [Applied Clinical Trials RSS — Insights on FDA Inspections of APAC Clinical Trial Sites and Their Quality Improvements](https://www.appliedclinicaltrialsonline.com/view/fda-inspections-reveal-quality-apac-clinical-trial-sites)

Source: https://www.cro.directory/posts/daily-news-2026-11-06-cro